Nitric oxide and schizophrenia: Present knowledge and emerging concepts of therapy

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 7, 2011, Pages 792-807

  Bernstein, Hans Gert ^a   Keilhoff, Gerburg ^a   Steiner, Johann ^a   Dobrowolny, Henrik ^a   Bogerts, Bernhard ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Animal models; Biochemistry; Blood; Brain; Cerebrospinal fluid; Genetics; Immunohistochemistry; Nitric oxide; Nitric oxide synthase(s); Schizophrenia; Therapy

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ARGININE; CHLORPROMAZINE; CLOZAPINE; CYCLIC GMP; DOPAMINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCINE; HALOPERIDOL; INDUCIBLE NITRIC OXIDE SYNTHASE; LYSINE; MINOCYCLINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPEPTIDE; NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITE; NORADRENALIN; OLANZAPINE; RISPERIDONE; SEROTONIN; TAURINE;

ALLELE; BRAIN; BRAIN CORTEX; BRAIN STEM; CELL FUNCTION; CELL MIGRATION; CEREBELLUM; CEREBROSPINAL FLUID; COGNITION; DISEASE COURSE; ENZYME ACTIVITY; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC LINKAGE; GENETIC POLYMORPHISM; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS; IMMUNOHISTOCHEMISTRY; METABOLISM; NERVE CELL; NERVOUS SYSTEM DEVELOPMENT; NERVOUS TISSUE; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; SCHIZOPHRENIA; SYNAPSE;

EID: 81155131944     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152711798072392     Document Type: Review

References (255)

1. Mesholam-Gately, R.I.; Giuliano, A.J.; Goff, K.P.; Faraone, S.V.; Seidman LJ. Neurocognition in first-episode schizophrenia: a metaanalysis and review. Neuropsychology, 2009, 23, 315-336.
2. ODonovan, M.C.; Craddock, N.J.; Owen, M.J. Genetics of psychosis; insights from views across the genome. Hum. Genet., 2009, 126, 3-12.
3. Walker, P.; Mittal, V.; Tessner, K. Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia. Annu. Rev. Clin. Psychol., 2008, 4, 189-216.
4. McCarley R.W, Wible C. G, Frumin M, Hirayasu Y.; Levitt, J.J.; Fischer, I.A.; Shenton, M.E. MRI anatomy of schizophrenia. Biol. Psychiatry, 1999, 45, 1099-1119.
5. Pakkenberg, B.; Scheel-Krüger, J.; Kristiansen, L.V. Schizophrenia; from structure to function with special focus on the mediodorsal thalamic prefrontal loop. Acta Psychiatr. Scand., 2009, 120, 45-354.
6. Andreasen, N.C.; O'Leary, D.S.; Flaum, M.; Nopoulos, P.; Watkins, G.L.; Boles Ponto, L.L.; Hichwa, R.D. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neurolepticnaïve patients. Lancet, 1997, 349(9067), 1730-1740.
7. Bernstein, H.-G.; Steiner, J.; Bogerts, B. Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy. Expert Rev. Neurother., 2009, 9, 1059-1071.
8. Calhoun, V.D.; Eichele, T.; Pearlson, G. Functional brain networks in schizophrenia: a review. Front. Hum. Neurosci., 2009; 3, 17.
9. Bogerts, B.; Steiner, J.; Bernstein, H.-G. Brain abnormalities in schizophrenia. In: Kasper, S.; Papadimitriou, G.N. Eds. Schizophrenia, Second Edition; Informa Healthcare: New York, 2009, 99-116.
10. Harrison, P.J. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain, 1999, 122, 593-624.
11. Bredt, D.S.; Snyder, S.H. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc. Natl. Acad. Sci. USA, 1990, 87, 682-685.
12. Dawson, T.M.; Snyder, S.H. Gases as biological messengers: nitric oxide and carbon monoxide in the brain. J. Neurosci., 1994, 14, 5147-5159.
13. Giraldi-Guimarães, A.; Bittencourt-Navarrete, E.E.; Mendez-Oter, R.C. Expression of neuronal nitric oxide synthase in the developing superficial layers of rat superior colliculus. Braz. J. Med. Biol. Res., 2004, 37, 869-877.
14. Akyol, O.; Zoroǧlu, S.S.; Armutcu F.; Sahin, S.; Gurel, A. Nitric oxide as a physiopathological factor in neuropsychiatric disorders. In vivo, 2004, 18, 377-390.
15. Kim, W.K.; Choi, Y.B.; Rayudu, P.V.; Das, P.; Asaad, W.; Arnelle, D.R.; Stamler, J.S.; Lipton, S.A. Attenuation of NMDA receptors and neurotoxicity by nitroxyl anion, NO-. Neuron, 1999, 24, 461-469.
16. Steinert, J.R.; Chernova, T.; Forsythe, I.D. Nitric oxide signaling in brain function, dysfunction, and dementia. Neuroscientist, 2010, 16, 435-452.
17. Kopieczna-Grzebieniak, E.; Goss, M. The importance of regulation of endogenous methylarginine concentrations in clinical practice. Przegl. Lek., 2005, 62, 1494-1501.
18. Mayer, B.; Hemmens, B. Biosynthesis and action of nitric oxide in mammalian cells. Trends Biochem. Sci., 1997, 22, 477-481
19. Weitzberg, E.; Hezel, M.; Lundberg J.O. Nitrate-nitrite-nitric oxide pathway: implications for anesthesiology and intensive care. Anesthesiology, 2010, 113, 1460-1475.
20. Bauer, V.; Sotníková, R. Nitric oxide - the endothelium-derived relaxing factor and its role in endothelial functions. Gen. Physiol. Biophys., 2010, 29, 319-340.
21. Calabrese, V.; Mancuso, C.; Calvani, M.; Rizzarelli, E.; Butterfield, D.A.; Stella, A.M. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat. Rev. Neurosci., 2007, 8, 766-775.
22. Sen, N.; Snyder, S.H. Protein modifications involved in neurotransmitter and gasotransmitter signaling. Trends Neurosci., 2010, 33, 493-502.
23. Culotta, E.; Koshland, E.D.E., Jr. NO news is good news. Science, 1992, 258, 1862-1865.
24. Bogdan, C. Nitric oxide and the regulation of gene expression. Trends Cell Sci., 2001, 11, 66-75.
25. Hemish, J.; Nakaya, N.; Mittal, V.; Enikolopov, G. Nitric oxide activates diverse signaling pathways to regulate gene expression. J. Biol. Chem., 2003, 278, 42321-42329.
26. Abbott, L.C.; Nahm, S.-S. Neuronal nitric oxide synthase expression in cerebellar mutant mice. Cerebellum, 2004, 3, 141-151.
27. Russwurm, M.; Koesling, D. Guanyl cyclase: NO hits its target. Biochem. Soc. Symp., 2004, 71, 51-63.
28. Hobbs, A.J.; Ignarro, L.J. Nitric oxide-cyclic GMP signal transduction system. Methods Enzymol., 1996, 269, 134-148.
29. Bredt, D.S.; Snyder, S.H. Nitric oxide, a novel neuronal messenger. Neuron, 1992, 8, 3-11.
30. Okada, D.; Yap, C.C.; Kojima, H.; Kikuchi, K.; Nagano, T. Distinct glutamate receptors govern differential levels of nitric oxide production in a layer-specific manner in the rat cerebellar cortex. Neuroscience, 2004, 125, 461-472.
31. 3H] dopamine uptake. Brain Res., 1994, 641, 83-91.
32. Boehning, D.; Snyder, S.H. Novel neural modulators. Annu. Rev. Neurosci., 2003, 26, 105-131.
33. Pepicelli, O.; Brescia, A.; Gherzi, E.; Reiteri, M.; Fedele, E. GABA(A), but not NMDA, receptors modulate in vivo NOmediated cGMP synthesis in rat cerebral cortex. Neuropharmacology, 2004, 46, 480-489.
34. Reif, A.; Herterich, S.; Strobel, A.; Ehlis, A.C.; Saur, D.; Jacob, C.P.; Wienker, T.; Töpner, T.; Fritzen, S.; Walter, U.; Schmitt, A.; Fallgatter, A.J.; Lesch, K.P. A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function. Mol. Psychiatry, 2006, 11, 286-300.
35. Kremeyer, B.; García, J.; Kymäläinen, H.; Wratten, N.; Restrepo, G.; Palacio, C.; Miranda, A.L.; López, C.; Restrepo, M.; Bedoya, G.; Brzustowicz, L.M.; Ospina-Duque, J.; Arbeláez, M.P.; Ruiz-Linares, A. Evidence for a role of the NOS1AP (CAPON) gene in schizophrenia and its clinical dimensions: an association study in a South American population isolate. Hum. Hered., 2008, 67,163-173.
36. Di Matteo, V.; Pierucci, M.; Benigno, A.; Esposito, E.; Crescimanno, G.; Di Giovanni, G. Critical role of nitric oxide on nicotine-induced hyperactivation of dopaminergic nigrostriatal system: Electrophysiological and neurochemical evidence in rats. CNS Neurosci. Ther., 2010, 16, 127-136.
37. Bernstein, H.-G.; Stanarius, A.; Baumann, B.; Henning, H.; Krell, D.; Danos, P.; Falkai, P.; Bogerts, B. Nitric oxide synthasecontaining neurons in the human hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of epressed patients and schizophrenics. Neuroscience, 1998a, 83, 867-875.
38. Ahern G.P.; Hsu, S.F.; Jackson, M.B. Direct actions of nitric oxide on rat neurohypophysial K+ channels. J. Physiol., 1999, 520, Pt 1,165-176.
39. Orlando, G.F.; Langnaese, K.; Landgraf, R.; Spina, M.G.; Wolf, G.; Engelmann, M. Neural nitric oxide gene inactivation affects the release profile of oxytocin into the blood in response to forced swimming. Nitric Oxide, 2007, 16, 64-70.
40. Wiklund, N.P.; Cellek, S.; Leone, A.M.; Iversen, H.H.; Gustafson, L.E.; Brundin, L.; Furst, V.W.; Flock, A.; Moncada, S. Visualisation of nitric oxide released by nerve stimulation. J. Neurosci. Res., 1997, 47, 224-232.
41. Kiss, J.P.; Vizi, E.S. Nitric oxide: A novel link between synaptic and nonsynaptic transmission. Trends Neurosci., 2001, 24, 211-215.
42. Nathan, C.; Xie, Q.W. Nitric oxide synthases: roles, tolls and controls. Cell, 1994, 78, 915-918.
43. Gross, S.S.; Wolin, M.S. Nitric oxide: pathophysiological mechanisms. Annu. Rev. Neurosci., 1995, 57, 737-769
44. Blaise, G.A.; Gauvin, D.; Gangal, M.; Authier, S. Nitric oxide, cell signaling and cell death. Toxicology, 2005, 208, 177-192.
45. Beckman, J.S.; Koppenol, W.H. Nitric oxide, superoxide, peroxynitrite: the good, the bad, the ugly. Am. J. Physiol., 1996, 271, C424-C432.
46. Noack, H.; Possel, H.; Rethfeldt, C.; Keilhoff, G.; Wolf, G. Peroxnitrite mediated damage and lowered superoxide tolerance in primary cortical glial cultures after induction of the inducible isoform of NOS. Glia, 1999, 28, 13-24.
47. Tohgi, H.; Abe, T.; Yamazaki, T.; Murata, C.; Isobe, C.; Ishizaki, E. The cerebrospinal fluid oxidized NO metabolites, nitrite and nitrate, in Alzheimeŕs disease and vascular dementia of Biswanger type and multiple small infarct type. J. Neural Transm., 1998, 105, 1238-1291.
48. Pou, S.; Keaton, L.; Surichamon, T.; Frigillana, P.; Rosen, G.M. Can nitric oxide be trapped by nitrone and nitrose compounds? Biochim. Biophys. Acta, 1994, 1201, 118-124.
49. Antunes, F.; Nunes, C.; Laranjinha, J.; Cadenas, E. Redox interaction of nitric oxide with dopamine and its derivatives. Toxicology, 2005, 208, 207-212.
50. Bitanihirwe, B.K.; Woo, T.U. Oxidative stress in schizophrenia: an integrated approach. Neurosci. Biobehav. Rev., 2011, 35, 878-893.
51. 3 H]-L-N -nitro-arginine autoradiography. Neuroscience, 1996, 75, 881-890.
52. Mungrue, I.N.; Bredt, D.S. nNOS at a glance: implications for brain and brawn. J. Cell Sci., 2004, 117, 2627-2629.
53. Christopherson, K.S.; Hillier, B.J.; Lim, W.A.; Bredt, D.S. PSD-95 assembles a ternary complex with the N-methyl-D-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain. J. Biol. Chem., 1999, 274, 27467-27473.
54. Sattler, R.; Xiong, Z.; Lu, W.Y.; Hafner, M.; MacDonald, J.F.; Tymianski, M. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science, 1999, 284, 1845-1848.
55. Gyurko, R.; Leupen, S.; Huang, P.L. Deletion of exon 6 of the neuronal nitric oxide synthase gene in mice results in hypogonadism and infertility. Endocrinology, 2002, 43, 2767-2774.
56. Bernstein, H.-G.; Keilhoff, G.; Seidel, B.; Stanarius, A.; Huang, P.L.; Fishman, M.C.; Reiser, M.; Bogerts, B.; Wolf, G. Expression of hypothalamic peptides in mice lacking neuronal nitric oxide synthase: reduced beta-END immunoreactivity in the arcuate nucleus. Neuroendocrinology, 1998b, 68, 403-411.
57. Langnaese, K.; Richter, K.; Smalla, K.H.; Krauss, M.; Thomas, U.; Wolf, G.; Laube, G. Splice-isoform specific immunolocalization of neuronal nitric oxide synthase in mouse and rat brain reveals that the PDZ-complex-building nNOSalpha beta-finger is largely exposed to antibodies. Dev. Neurobiol., 2007, 67, 422-437.
58. Kirchner, L.; Weitzdorfer, R.; Hoeger, H.; Uri, A.; Schmidt, P.; Engelmann, M.; Villar, S.R.; Fountoulakis, M.; Lubec, G.; Lubec, B. Impaired cognitive performances in neuronal nitric oxide synthase knockout mice is associated with hippocampal protein derangements. Nitric Oxide, 2004, 11, 316-330.
59. Kim, H.L.; Park, Y.S. Maintenance of cellular tetrahydrobiopterin homeostasis. BMB Rep., 2010, 43, 584-592.
60. Jaffrey, S.R.; Snyder, S.H. PIN: an associated protein inhibitor of neuronal nitric oxide synthase. Science, 1996, 274, 774-777
61. Wang, G.; Hu, C.; Jiang, T.; Luo, J.; Hu, J.; Ling, S.; Liu, M.; Xing, G. Overexpression of serotonin receptor and transporter mRNA in blood leukocytes in antipsychotic-free and antipsychotic-naïve schizophrenic patients: gender differences. Schizophr. Res., 2010, 121, 160-171.
62. Hsieh, C.J.; Chen, Y.C.; Lai M.S.; Hong, C.J.; Chien, K.L. Genetic variability in serotonin receptor and transporter genes may influence risk for tardive dykinesia in chronic schizophrenia. Psychiatry Res., 2011, 188(1), 175-176.
63. Lin C.; Tang, W.; Hu, J.; Gao, L.; Huang, K.; Xu, Y.; He, G.; Liang, P.; Feng, G.; He, L.; Shi, Y. Haplotype analysis confirms association of the serotonin transporter (5-HTT) gene with schizophrenia in the Han Chinese population. Neurosci. Lett., 2009, 453, 210-213.
64. Chanrion, B.; Mannoury la Cour, C.; Bertaso, F.; Lerner-Natoli, M.; Freissmuth, M.; Millan, M.J.; Bockaert, J.; Marin, P. Physical interaction between the serotonin transporter and neuronal nitric oxide synthase underlies reciprocal modulation of their activity. Proc. Natl. Acad. Sci. USA, 2007, 104, 8119-8124.
65. Liu, B.; Xu H, Paton, J.F.; Kasparov, S. Cell- and region-specific miR30-based gene knock-down with temporal control in the rat brain. BMC Mol. Biol., 2010, 6, 93.
66. Bernstein, H.-G.; Jirikowski, G.F.; Heinemann, A.; Baumann, B.; Hornstein, C.; Danos, P.; Diekmann, S.; Sauer, H.; Keilhoff, G.; Bogerts, B. Low and infrequent expression of nitric oxide synthase/NADPH diaphorase in neurons of the human supraoptic nucleus: a histochemical study. J. Chem. Neuroanat., 2000, 20, 177-183.
67. Bernstein, H.G.; Bogerts, B.; Keilhoff, G. The many faces of nitric oxide in schizophrenia: a review. Schizophr. Res., 2005a, 78, 69-86.
68. Blum-Degen D.; Heinemann, T.; Lan, J.; Pedersen, V.; Leblhuber, P.; Riederer, P.; Gerlach, M. Characterization and regional distribution of nitric oxide synthase in the human brain during normal aging. Brain Res., 1999, 834, 128-135.
69. Egberongbe, Y.I.; Gentleman, S.M.; Falkai, P.; Bogerts, B.; Polak, J.M.; Roberts, G.W. The distribution of nitric oxide synthase immunoreactivity in human brain. Neuroscience, 1994, 59, 561-578.
70. Bernstein, H.-G.; Brisch, R.; Ogunlade, V.; Heinemann, A.; Baumann, B.; Arendt, T.; Dobrowolny, H.; Bogerts, B.; Lüth, H.-J. Detection of nitric oxide synthase (NOS) immunoreactive neurons in the human septal area: a matter of method? J. Chem. Neuroanat., 2004a, 27, 247-250.
71. Snyder, S.H.; Bredt, D.S. Nitric oxide as a neuronal messenger. Trends Pharmacol. Sci., 1991, 12, 125-128.
72. Kawakami, S.; Ichikawa, M.; Yokosuka, M.; Tsukamura, H.; Maeda, K. Glial and neuronal localization of the neuronal nitric oxide synthase immunoreactivity in the median eminence of female rats. Brain Res., 1998, 789, 322-326.
73. Stanarius, A.; Seidel, B.; Wolf, G. Neuronal nitric oxide synthase in the vasculature of the rat brain: an immunohistochemical study using the tyramine signal amplification technique. J. Neurocytol., 1998, 27, 731-736.
74. Furchgott, R.F.; Zawadzki, J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature, 1980, 288, 373-376.
75. Endres, M.; Laufs, U.; Liao, J.K.; Moskowitz, M.A. Targeting eNOS for stroke protection. Trends Neurosci., 2004, 27, 283-289
76. Fleming, I.; Busse, R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am. J. Physiol., 2003, 284, R1-R12.
77. Andreasen, N.C. Brain imaging: applications in psychiatry. Science, 1988, 239, 1381-1388.
78. Galea, E.; Feinstein, D.I. Regulation of the expression of the inflammatory nitric oxide synthase (NOS2) by cyclic AMP. FASEB J., 1999, 13, 2125-2137.
79. Acarin, L.; Peluffo, H.; Barbeito, L.; Castello, B.; Gonzales, B. Astroglial nitration after postnatal excitotoxic damage: correlation with nitric oxide sources, cytoskeletal, apoptotic and antioxidant proteins. J. Neurotr., 2005, 22, 189-200.
80. Boje, K.M.; Arora, P.K. Microglial-produced nitric oxide and reactive nitric oxides mediate neuronal cell death. Brain Res., 1992, 587, 250-256.
81. Stoll, G.; Jander, S.; Schroeter, M. Detrimental and beneficial effects of injuryinduced inflammation and cytokine expression in the nervous system. Adv. Exp. Med. Biol., 2002, 513, 87-113.
82. Birch, R.E.; Polmar S.H. Pharmacological modification of immunoregulatory T lymphocytes. I. Effect of adenosine, H1 and H2 histamine agonists upon T lymphocyte regulation of B lymphocyte differentiation in vitro. Clin. Exper. Immunol., 1982, 48, 218-230.
83. Knudsen, P.J.; Dinarello, C.A.; Strom, T.B. Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity. by increasing. intracellular. cyclic. adenosine monophosphate. J. Immunol., 1986, 137, 3189-3194.
84. Fernandez-Vizarra, R.J.; Castro-Blanco, S.; Ventura, M.L.; Nieto, M.; Gomez-Isla, T.; Martinez-Murillo, R.; Martinez, A.; Serrano, J.; Fernandez, A.P. Nitric oxide in the cerebral cortex of amyloid precursor protein in (SW) Tg2576 transgenic mice. Neuroscience, 2004, 128, 73-89.
85. Ganzinelli, S.; Borda, E.; Sterin-Borda, L. Autoantibodies from schizophrenia patients induce cerebral cox-1/iNOS mRNA expression with NO/PGE2/MMP-3 production. Int. J. Neuropsychopharmacol., 2010, 13, 293-303.
86. Kato, T.; Monji, A.; Hashioka, S.; Kanba, S. Risperidone significantly. inhibits. interferon-gamma-induced microglial activation in vitro. Schizophr. Res., 2007, 92, 108-115.
87. Leiper, J.; Vallance, P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc. Res., 1999, 43, 542-548.
88. Ramirez J.; Garnica, R.; Boll, M.-C.; Montes, S.; Rios C. Low concentration of nitrite and nitrate in cerebrospinal fluid from schizophrenic patients; a pilot study. Schizophr. Res., 2004, 86, 357-361.
89. Keilhoff, G.; Seidel, B.; Noack, H.; Stanek, D.; Wolf, G. Patterns of nitric oxide synthase at the messenger RNA and protein levels during early rat brain development. Neuroscience, 1996, 75, 1193-1201.
90. 3H]. L-NG-nitroarginine labelling to measure cerebellar nitric oxide synthase in patients with schizophrenia. Neurosci. Lett., 1995, 202, 49-52.
91. Keilhoff, G.; Wolf, G. Citrulline immunohistochemistry may not necessarily identify nitric oxide synthase activity: the pitfall of peptidylarginine deiminase. Nitric Oxide, 2003, 8, 31-38.
92. Lüth, H.-J.; Münch, G.; Arendt, T. Aberrant expression of NOS isoforms in Alzheimeŕs disease is structurally related to nitrotyrosine formation. Brain Res., 2002, 953, 135-143.
93. Pomper, M.G.; Musachio, J.L.; Scheffel, U.; MacDonald, J.E.; McCarthy, D.J.; Reif, D.W.; Villemagne, V.L.; Yokoi, F.; Dannalös, R.F.; Wong, D.F. Radiolabeled neuronal nitric oxide synthase inhibitors: synthesis, in vivo evaluation, and primate PET studies. J. Nucl. Med., 2000, 41,1417-1425.
94. Averbukh, M.L.; Kasko, A.F.; Nikolenko, E.S.; Rybas, I.I. On the diagnostic significance of Blacḱs reaction in psychiatric patients. Lab. Delo, 1966, 5, 289-291.
95. Buĺba, P.A.; Kaśko, A.F.; Averbukh, M.L.; Nikolenko, E.S. Peculiarities of the Black reaction and white phenomenon in mental patients. Lab. Delo, 1968, 6, 350-352.
96. Vincent, S.R.; Hope, B.T. Neurons that say NO. Trends Neurosci., 1992, 15, 108-113.
97. Karson, C.N.; Garcia-Rill, E.; Biedermann, J.; Mrak, R.E.; Husain, M.M.; Skinner, R.D. The brain stem reticular formation in schizophrenia. Psychiatry Res., 1991, 40, 31-48.
98. Karson, C.N.; Griffin, W.S.T.; Mrak, R.E.; Husain, M.; Dawson, T.M.; Snyder, S.H.; Moore, N.C.; Sturner, W.Q. Nitric oxide synthase (NOS) in schizophrenia: Increases in cerebellar vermis. Mol. Chem. Neuropathol., 1996, 27, 275-284.
99. Das, I.; Khan, N.S.; Puri, B.K.; Sooranna, S.R.; de Belleroche, J.; Hirsch, S.R. Elevated platelet calcium mobilization and nitric oxide synthase activity may reflect abnormalities in schizophrenic brain. Biochem. Biophys. Res. Commun., 1995, 212, 375-380.
100. Sullivan, P.F.; Kendler, K.S.; Neale, M.C. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch. Gen. Psychiatry, 2003, 60, 1187-1192.
101. Shinkai T.; Ohmori, O.; Hori, H.; Nakamura, J. Allelic association of the neuronal nitric oxide synthase (NOS1) gene with schizophrenia. Mol. Psychiatry, 2002, 7, 560-563.
102. Liou Y.-J.; Tsai, S.-J.; Hong, C.-J.; Liao, D.-L. Association analysis for the CA repeat polymorphism of the neuronal nitric oxide (NOS1) gene and schizophrenia. Schizophr. Res., 2003, 65, 57-59.
103. Shinkai T.; Ohmori, O.; Matsumoto, C.; Hori, H.; Kennedy, J.L.; Nakamura, J. Genetic association analysis of neuronal nitric oxide gene polymorphism with tardive dyskinesia. Neuromolec. Med., 2004, 5, 163-170.
104. Wang Y.C.; Liou, Y.J.; Liao, D.L.; Bai, Y.M.; Lin, C.C.; Yu, S.C.; Chen, J.Y. Association analysis of a neural nitric oxide synthase gene polymorphism and antipsychotics-induced tardive dyskinesia in Chinese schizophrenic patients. J. Neural Transm., 2004, 111, 623-629.
105. Silberberg, G.; Ben-Shachar, D.; Navon, R. Genetic analysis of nitric oxide synthase 1 variants in schizophrenia and bipolar disorder. Am. J. Med. Genet. B. Neuropsychiatr. Genet., 2010, 153B, 1318-1328.
106. Tang W.; Huang, K.; Tang R, Zhou, G.; Fang, C.; Zhang, J.; Du, L.; Feng, G.; He, L.; Shi, Y. Evidence for association between the 5' flank of the NOS1 gene and schizophrenia in the Chinese population. Int. J. Neuropsychopharmacol., 2008, 11, 1063-1071
107. Cui, H.; Nishiguchi, N.; Yan, Hishimoto A. A putative cis-acting polymorphism in the NOS1 gene is associated with schizophrenia and NOS1 immunoreactivity in the postmortem brain. Schizophr Res., 2010,121, 172-178.
108. Donohoe, G.; Walters, J.; Morris, D.W.; Quinn, E.M.; Judge, R.; Norton, N.; Giegling, I.; Hartmann, A.M.; Möller, H.J.; Muglia, P.; Williams, H.; Moskvina, V.; Peel, R.; O'Donoghue, T.; Owen, M.J.; O'Donovan, M.C.; Gill, M.; Rujescu, D.; Corvin A. Influence of NOS1 on verbal intelligence and working memory in both patients with schizophrenia and healthy control subjects. Arch. Gen. Psychiatry, 2009, 66, 1045-1054.
109. Okumura, T.; Okochi, T.; Kishi T, Ikeda, M.; Kitajima, T.; Yamanouchi Y.; Kinoshita, T.; Kawashima, K.; Tsunoka, T.; Ujik, H.; Inada, T.; Ozaki, N.; Iwata, N. No association between polymorphisms of neuronal oxide synthase 1 gene (NOS1) and schizophrenia in a Japanese population. Neuromolecular Med., 2009, 11, 123-127.
110. Brzustowicz, L.M.; Siomone, J.; Mohseni, P.; Hayter, J.E.; Hodgkinson, K.A.; Chow, E.W.; Bassett, A.S. Linkage disequilibrium mapping of schizophrenia susceptibility to the CAPON region of chrosomome 1q22. Am. J. Hum. Genet., 2004, 74, 1057-1063.
111. Brzustowicz, L. NOS1AP in schizophrenia. Curr. Psychiatry Rep., 2008, 10, 158-163.
112. Zheng Y.; Li, H.; Quin, W.; Duan, Y.; Xiao, Y.; Li, C.; Zhang, J.; Li, X.; Feng, G.; He, L. Association of the carboxy-I-terminal PDZ ligand of the neuronal nitric oxide synthase gene with schizophrenia in the Chinese Han population. Biochem. Biophys. Res. Commun., 2005, 328, 809-815.
113. Puri V.; McQuillin, A.; Thirumalai, S.; Lawrence, J.; Krasucki, R.; Choudhury, K.; Datta, S.; Kerwin, S.; Quested, D.; Bass, N.; Pimm, J.; Lamb G, Moorey, H.; Kandasami, G.; Badacsonyi, A.; Kelly, K.; Morgan, J.; Punukollu, B.; Nadeem, H.; Curtis, D.; Gurling, H.M. Failure to confirm allelic association between markers at the CAPON gene locus and schizophrenia in a British sample. Biol. Psychiatry, 2006, 59,195-197.
114. Wratten, N.S.; Memoli, H.; Huang, Y.; Dulencin, A.M.; Matteson, P.G.; Cornacchia M.A, Azaro M.A.; Messenger, J. Hayter J.E.; Bassett, A.S.; Buyske, S.; Millonig, J.H.; Vieland, V.J.; Brzustowicz, L.M. Identification of a schizophrenia-associated functional noncoding variant in NOS1AP. Am. J. Psychiatry, 2009,166, 434-441.
115. Chissoe, S.; Ehm, M.G.; Jean, St. P. Genes associated with schizophrenia. US Patent Appl., 2008, 20080176239, p. 80
116. Liou, Y.J.; Lai, I.C.; Lin, M.W.; Bai, Y.M.; Lin, C.C.; Liao, D.L.; Chen, J.Y.; Lin, C.Y.; Wang Y.C. Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and tardive dyskinesia in patients with schizophrenia. Pharamogenet. Genomics, 2006, 16, 151-157.
117. Kawohl W.; Giegling, I.; Mavrogiorgou, P.; Pogarell, O.; Mulert C.; Möller, H.J.; Hegerl, U.; Rujescu, D.; Juckel G. Association of functional polymorphisms in NOS1 and NOS3 with loudness dependence of auditory evoked potentials. Int. J. Neuropsychopharmacol., 2008, 11, 477-483.
118. Oliveira, J.P.; Zuardi, A.W.; Hallak, J.E. Role of nitric oxide in patients with schizophrenia a systematic review of the literature. Curr. Psychiatry Rev., 2008, 4, 219-227.
119. Akbarian, S.; Bunney, W.E. Jr.; Potkin, S.G.; Wigal, S.B.; Hagman, J.O.; Sandman, C.A.; Jones, E.G. Altered distribution of nictotinadenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch. Gen. Psychiatry, 1993a, 50, 169-177.
120. Akbarian S.; Viñuela A.; Kim, J.J.; Potkin, S.G.; Bunney, W.E. Jr.; Jones, E.G. Distorted distribution of nicotinamide adenine dinucleotidephosphate diaphorase neurons in temporal lobe of schizophrenica implies anomalous cortical development. Arch. Gen. Psychiatry, 1993b, 50, 178-187.
121. Akbarian S.; Kim, J.J.; Potkin, S.G.; Hetrick, W.P.; Bunney, W.E. Jr.; Jones, E.G. Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patients. Arch. Gen. Psychiatry, 1996, 53, 425-436.
122. Eastwood, S.L.; Harrison, P.J. Interstitial white matter neurons express less reelin and are abnormally distributed in schizophrenia: towards an integration of molecular and morphologic aspects of the neurodevelopmental hypothesis. Mol. Psychiatry, 2003, 8, 821-831
123. Kostovi, I.; Juda, M.; Sedmak G. Developmental history of the subplate zone, subplate neurons and interstitial white matter neurons: relevance for schizophrenia. Int. J. Dev. Neurosci., 2011, 29, 193-205.
124. Benes, F.M.; Berretta, S. GABAergic interneurons: implications for understanding. schizophrenia. and. bipolar. disorder. Neuropsychopharmacology, 2001, 25, 1-27.
125. Connor, C.M.; Guo, Y.; Akbarian S. Cingulate white matter neurons in schizophrenia and bipolar disorder. Biol. Psychiatry, 2009, 66, 486-493.
126. Yang, Y.; Fung, S.J.; Rothwell, A.; Tianmei, S.; Weickert, C.S. Increased interstitial white matter neuron density in the dorsolateral prefrontal cortex of people with schizophrenia. Biol. Psychiatry, 2011, 69, 63-70.
127. Xing, G.; Chavko, M.; Zhang, L.-X.; Yang, S.; Post, R.M. Decreased calcium-dependent constitutive nitric oxide synthase (cNOS) activity in prefrontal cortex in schizophrenia and depression. Schizophr. Res., 2002, 58, 21-30.
128. Baba, H.; Suzuki, T.; Arai, H.; Emson, P.C. Expression of Nnos and soluble guanylate cyclase in schizophrenic brain. Neuroreport, 2004, 15, 677-680.
129. Kristofiková, Z.; Kozmiková, I.; Hovorková, P.; Rícn, J.; Zach, P; Majer, E.; Klaschka, J.; Rípová, D. Lateralization of hippocampal nitric oxide mediator system in people with Alzheimer disease, multi-infarct dementia and schizophrenia. Neurochem. Int., 2008, 53, 118-125.
130. Oliveira, R.M.; Guimarães, F.S.; Deakin, J.F. Expression of neuronal nitric oxide synthase in the hippocampal formation in affective disorders. Braz. J. Med. Biol. Res., 2008, 41, 333-341.
131. Bernstein, H.G.; Heinemann, A.; Steiner, J.; Bogerts, B. Schizophrenia, sleep disturbances and the suprachiasmatic nucleus: reduced nitric oxide synthase may matter. Med. Hypotheses, 2010a, 74, 397-398.
132. Bernstein, H.G.; Keilhoff, G.; Steiner, J.; Dobrowolny, H.; Bogerts, B. The hypothalamus in schizophrenia research: No longer a wallflower existence. Open Neuroendocriol. J., 2010b, 3, 59-67
133. Raadsheer, F.C.; Hoogendijk, W.J.G.; Stam, F.C.; Tilders, F.J.; Swaab, D.F. Increased number of corticotropin-releasing hormone neurons in the hypothalamic paraventricular nuclei of depressed patients. Neuroendocrinology, 1994, 60, 436-444.
134. Ryan, M.C.; Sharifi, N.; Condren, R.; Thakore, J.H. Evidence of basal pituitary-adrenal overactivity in first episode, drug naïve patients with schizophrenia. Psychoneuroendocrinology, 2004, 29, 1065-1070.
135. Rosen, Y.; Reznik, I.; Sluvis, A.; Kaplan, D.; Mester, R. The significance of the nitric oxide in electro-convulsive therapy: a proposed neurophysiological mechanism. Med. Hypotheses, 2003, 60, 424-429.
136. Bernstein, H.-G.; Heinemann, A.; Bogerts, B. Electro-convulsive therapy, nitric oxide and HPA axis: a closer look at human hypothalamus. Med. Hypotheses, 2004b, 62, 158-159.
137. Corcoran, C.; Walker, E.; Huot, R.; Mittal, V.; Tessner, K.; Kestler, L.; Malaspina, D. The stress cascade and schizophrenia: etiology and onset. Schizophr. Bull., 2003, 29, 671-692.
138. Bernstein, H.-G.; Heinemann, A.; Krell, D.; Dobrowolny, H.; Bielau, H.; Keilhoff, G.; Bogerts, B. Hypothalamic nitric oxide synthase in affective disorder: Focus on the suprachiasmatic nucleus. Cell Mol. Biol., 2005b, 51, 279-284.
139. Trbovic, S.N. Schizophrenia as a possible dysfunction of the suprachiasmatic nucleus. Med. Hypotheses, 2010, 74, 127-131.
140. Chen, L.; Majde, J.A.; Krueger, J.M. Spontaneous sleep in mice with targeted disruptions of neuronal or inducible nitric oxide synthase genes. Brain Res., 2003, 973, 214-222.
141. Kalinchuk, A.V.; Stenberg, D.; Rosenberg, P.A.; Porkka-Heiskanen, T. Inducible and neuronal nitric oxide synthases (NOS) have complimentary roles in recovery sleep induction. Eur. J. Neurosci., 2010, 24, 1443-1456.
142. Yao, J.K.; Leonard, S.S.; Reddy, R.D. Increased nitric oxide radicals in post-mortem brains from schizophrenic patients. Schizophr. Res., 2001, 49, 58.
143. Lauer, M.; Johannes, S.; Fritzen, S.; Senitz, D.; Riederer, P.; Reif, A. Morphological abnormalities in nitric-oxide-synthase-positive striatal. interneurons. of. schizophrenic. patients. Neuropsychobiology, 2005, 52, 111-117.
144. Fritzen, S.; Lauer, M.; Schmitt, A.; Töpner, T.; Strobel, A.; Lesch, K.P.; Reif, A. NO synthase-positive striatal interneurons are decreased in schizophrenia. Eur. Neuropsychopharmacol., 2007, 17, 595-599.
145. Garcia-Hill, E.; Biedermann, J.A.; Chambers, T.; Skinner, R.D.; Mrak, R.E.; Husain, M.; Karson, C.N. Mesopontine neurons in schizophrenia. Neuroscience, 1995, 66, 321-335.
146. Axer, H.; Bernstein, H.-G.; Keiner S.; Heronimus, P.; Sauer, H.; Witte, O.W.; Bogerts, B.; Bär, K.-J. Increased neuronal cell number in the dorsal motor nucleus of the vagus in schizophrenia. Acta Neuropsychiatr., 2010, 22, 26-34.
147. Bernstein, H.-G.; Krell, D.; Braunewell, K.H.; Baumann, B.; Gundelfinger, E.D.; Diekmann, S.; Danos, P.; Bogerts, B. Increased number of nitric oxide synthase immunoreactive Purkinje cells and dentate nucleus neurons in schizophrenia. J. Neurocytol., 2001, 30, 661-670.
148. Bullock, W.M.; Cardon, K.; Bustillo, J.; Roberts, R.C.; Perrone-Bizzozero, N.I. Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia patients. Am. J. Psychiatry, 2008, 165, 1594-1603.
149. Ho, B.C.; Mola, C.; Andreasen, N.C. Cerebellar dysfunction in neuroleptic naive schizophrenia patients: clinical, cognitive, and neuroanatomic correlates of cerebellar neurologic signs. Biol. Psychiatry, 2004, 55, 1146-1153.
150. Ende, G.; Hubrich, P.; Walter, S.; Weber-Fahr, W.; Kammerer, N.; Braus, D.F.; Henn, F.A. Further evidence for altered cerebellar integrity in schizophrenia. Am. J. Psychiatry, 2005, 162, 790-792
151. Hadzimichalis, N.M.; Previtera, M.L.; Moreau, M.P.; Li, B.; Lee, G.H.; Dulencin, A.M.; Matteson, P.G.; Buyske, S.; Millonig, J.H.; Brzustowicz, L.M.; Firestein, B.L. NOS1AP protein levels are altered in BA46 and cerebellum of patients with schizophrenia. Schizophr. Res., 2010, 124, 248-250.
152. Das, I.; Khan, N.S.; Puri, B.K.; Sooranna, S.R.; de Belleroche, J.; Hirsch, S.R. Elevated platelet calcium mobilization and nitric oxide synthase activity may reflect abnormalities in schizophrenic brain. Biochem. Biophys. Res. Commun., 1995, 212, 375-380.
153. Das, I.; Khan, N.S.; Puri, B.K.; Hirsch, S.R. Elevated endogenous nitric oxide synthase inhibitor in schizophrenic plasma may reflect abnormalities in brain nitric oxide production. Neurosci. Lett., 1996, 215, 209-211.
154. Zoroǧlu, S.S.; Herken, H.; Yurekli, M.; Uz, E.; Tutkun, H.; Savas, H.A.; Bagei, C.; Ozen, M.E.; Cengiz, B.; Cakmak, E.A.; Dogru, M.I.; Akyol, Ö. The possible pathophysiological role of plasma nitric oxide and adrenomedullin in schizophrenia. J. Psychiatr. Res., 2002, 36, 309-315.
155. Taneli, F.; Piridar, S.; Akdeniz, F.; Uyanik, B.S.; Ari, Z. Serum nitric oxide metabolite levels and the effect of antipsychotic therapy in schizophrenia. Arch. Med. Res., 2004, 35, 401-405.
156. Yilmaz, N.; Herken, H.; Cicek, H.K.; Celik, A.; Yürekli, M.; Akyol, O. Increased levels of nitric oxide, cortisol and adrenomedullin in patients with chronic schizophrenia. Med. Princ. Pract., 2007,16, 37-41.
157. Djordjevi, V.V.; Stojanovi, I; Stankovi-Ferlez, D.; Risti, T; Lazarevi D.; Cosi, V.; Djordjevi VB. Plasma nitrite/nitrate concentrations in patients with schizophrenia. Clin. Chem. Lab. Med., 2010, 48, 89-94.
158. Herken, H.; Uz, E.; Özyurt, H.; Akyol, Ö. Red blood cell nitric oxide levels in patients with schizophrenia. Schizophr. Res., 2001, 52, 289-290.
159. Srivastava, N.; Barthwal, M.K.; Dalal, P.K.; Agarwal, A.K.; Nag, D.; Srimal, R.C.; Seth, P.K.; Dikshit, M. Nitrite content and antioxidant enzyme levels in the blood of schizophrenic patients. Psychopharmacology, 2001, 158, 140-145.
160. Suzuki, E.; Nakaki, T.; Nakamura, M.; Miyaoka, H. Plasma nitrate levels in deficit versus non-deficit forms of schizophrenia. J. Psychiatr. Neurosci., 2003, 28, 288-292.
161. Lee, B.H; Kim, Y.K. Reduced plasma nitric oxide metabolites before and after antipsychotic treatment in patients with schizophrenia compared to controls. Schizophr Res., 2008, 104, 36-43.
162. Nakano, Y.; Yoshimura, R.; Nakano, H.; Ikenouchi-Sugita, A.; Hori, H.; Umene-Nakano, W.; Ueda, N.; Nakamura, J. Association between plasma nitric oxide metabolites levels and negative symptoms of schizophrenia: a pilot study. Hum. Psychopharmacol., 2010, 25, 139-144.
163. Atmaca, M.; Tezcan, E.; Ustundag, B. Plasma nitric oxide and leptin values in patients with olanzapine-induced weight gain. J. Psychiatr. Res., 2007, 41, 74-79.
164. Yanik, M.; Vural, H.; Kocyiǧit, P.; Tutkun, H.; Zoroǧlu, S.S.; Herken, H.; Sava, H.A.; Köylü, A.; Akyol, O. Is the arginine-nitric oxide oxide pathway involved in the pathogenesis of schizophrenia? Neuropsychobiology, 2003a, 47, 61-65.
165. Yanik, M.; Vural, H.; Tutkun, H.; Zoroǧlu, S.S.; Savas, H.A.; Herken, H; Kocyiǧit, A.; Keles, H.; Akyol, O. The role of the arginine-nitric oxide pathway in the pathogenesis of bipolar affective disorder. Eur. Arch. Psychiatry Clin. Neurosci., 2003b, 254, 43-47.
166. Richardson, M.A.; Read, L.L.; Reilly, M.A.; Clelland, J.D.; Clelland, C.L. Analysis of plasma biopterin levels in psychiatric disorders suggests a common BH4 deficit in schizophrenia and schizoaffective disorder. Neurochem. Res., 2007, 32, 107-113.
167. Szilagyi, A.K. Untersuchungen über die Arginase-aktivität der Cerebrospinalflüssigkeit. J. Neurol. Sci. 1973, 18, 143-154
168. Wiesinger, H. Arginine metabolism and the synthesis of nitric oxide in the nervous system. Prog. Neurobiol., 2001, 64, 365-391
169. Masuda, H.; Azuma H. Biological and pathophysiological roles of endogenous methylarginines as inhibitors of nitric oxide synthase. Nippon Yakurigaku Zasshi, 2002, 119, 29-35.
170. Tandon, R.; Nasrallah, H.A.; Keshavan, M.S. Schizophrenia, just the facts 5. Treatment and prevention. Past, present, and future. Schizophr. Res., 2010, 122, 1-23.
171. Vleeming, W.; Rambali, B.; Opperhuizen, A. The role of nitric oxide in cigarette smoking and nicotine addiction. Nicotine Tob. Res., 2002, 4, 313-318.
172. Keser, A.; Balkan, B.; Gozen, O.; Kanit, L.; Pogun, S. Hippocampal neuronal nitric oxide synthase (nNOS) is regulated by nicotine and stress in female but not in male rats. Brain Res., 2011, 1368, 134-142.
173. Lipska, B.K. Using animal models to test a neurodevelopmental hypothesis of schizophrenia. J. Psychiatry Neurosci. 2004, 29, 282-286.
174. Nestler, E.J.; Hyman, S.E. Animal models of neuropsychiatric disorders. Nat. Neurosci., 2010, 13, 1161-119.
175. Fejgin, K.; Pålsson, E.; Wass, C.; Finnerty, N.; Lowry, J.; Klamer, D. Prefrontal GABA(B) receptor activation attenuates phencyclidine-induced impairments of prepulse inhibition: involvement of nitric oxide. Neuropsychopharmacology., 2009, 34, 1673-1684.
176. Pålsson, E.; Finnerty, N.; Fejgin, K.; Klamer, D.; Wass, C.; Svensson, L.; Lowry, J. Increased cortical nitric oxide release after phencyclidine administration. Synapse., 2009, 63, 1083-1088.
177. Klamer, D.; Engel, J.A.; Svensson, L. The neuronal nitric oxide synthase inhibitor, N-omega-propyl-L-arginine, blocks the effects of phencyclidine on prepulse inhibition and locomotor activity in mice. Eur. J. Pharmacol., 2004a, 503, 103-107.
178. Klamer, D.; Engel, J.A.; Svensson, L. Phencyclidine-induced behavior in mice prevented by methylene blue. Basic Clin. Pharmacol. Toxicol., 2004b, 94, 65-72.
179. Klamer, D.; Zhang, J.; Engel, J.A.; Svensson, L. Selective interaction of nitric oxide synthase inhibition with phencyclidine: behavioural and NMDA receptor binding studies in the rat. Behav. Brain Res., 2005, 159, 95-103.
180. Wass, C.; Klamer, D.; Fejgin, K.; Pålsson E. The importance of nitric oxide in social dysfunction. Behav. Brain Res., 2009, 200, 113-116.
181. Pålsson, E.; Lowry, J.; Klamer D. Information processing deficits and nitric oxide signalling in the phencyclidine model of schizophrenia. Psychopharmacology, 2010, 212, 643-651.
182. Wiley, J.L.; Golden, K.M.; Bowen, S.E. Effects of modulation of nitric oxide on acoustic startle responding and prepulse inhibition in rats. Eur. J. Pharmacol., 1997, 328, 125-130.
183. Bujas-Bobanovic, M.; Robertson, H.A.; Dursun, S.M. Effects of nitric oxide synthase inhibitor N(G)-nitro-L-arginine methyl ester on phencycldine-induced effects in rats. Eur. J. Pharmacol., 2000, 409, 57-65.
184. Bird, D.C.; Bujas-Bobanovic, M.; Robertson, H.A.; Durson, S.A. Lack of phencyclidine-induced effects in mice with reduced neuronal nitric oxide synthase. Psychopharmacology, 2001, 155, 299-309.
185. Becker, A.; Paters, B.; Schröder, H.; Mann, T.; Hüther, G.; Grecksch, G. Ketamine-induced changes in rat behavior: a possible animal model of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2003, 27, 687-700.
186. Keilhoff, G.; Becker, A.; Grecksch, G.; Wolf, G.; Bernstein, H.-G. Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia. Neuroscience, 2004a, 126, 591-598.
187. Keilhoff, G.; Bernstein, H.-G.; Becker, A.; Grecksch, G.; Wolf, G. Increased neurogenesis in a rat ketamine model of schizophrenia. Biol. Psychiatry, 2004b, 56, 317-322.
188. Packer, M.A.; Stasiv, Y.; Benraiss, A.; Chmielnicki, E.; Grinberg, A.; Westphal, H.; Goldman, S.A.; Enikolopov, G. Nitric oxide negatively regulates mammalian adult neurogenesis. Proc. Natl Acad. Sci. USA, 2003, 100, 9566-9571.
189. Packer, M.A.; Hemish, J.; Mignone, J.L.; John, S.; Pugach, I.; Enikolopov, G. Transgenic mice overexpressing nNOS in the adult nervous system. Cell Mol. Biol., 2005, 51, 269-277.
190. Black, M.D.; Selk, D.E.; Hitchcock, J.M.; Wettstein, J.G.; Sörensen, S.M. On the effect of neonatal nitric oxide synthase inhibition in rats: a potential neurodevelopmental model of schizophrenia. Neuropharmacology, 1999, 38, 1299-1306.
191. Black, M.D.; Simmonds, J.; Senyah, Y.; Wettstein, J.G. Neonatal nitric oxide synthase inhibition: social interaction deficits in adulthood. and. reversal. by. antipsychotic. drugs. Neuropharmacology, 2002, 42, 414-420.
192. Salum, C.; Guimarães, F.S.; Brandão, M.L.; Del Bel, E.A. Dopamine and nitric oxide interaction on the modulation of prepulse inhibition of the acoustic startle response in the Wistar rat. Psychopharmacology, 2006, 85, 33-41.
193. Morales-Medina, J.C.; Mejorada, A.; Romero-Curiel, A.; Aguilar-Alonso, P.; León-Chávez, B.A.; Gamboa, C.; Quirion, R.; Flores, G. Neonatal administration of N-omega-nitro-L-arginine induces permanent decrease in NO levels and hyperresponsiveness to locomotor activity by D-amphetamine in postpubertal rats. Neuropharmacology., 2008, 55, 1313-1320.
194. Deutsch, S.I.; Rosse, R.B.; Schwartz, B.L.; Fay-McCarthy, M.; Rosenberg, P.; Fearing, K. Methylene blue adjuvant therapy of schizophrenia. Clin. Neuropharmacol., 1997, 20, 357-363.
195. Tarazi, F.I.; Zhang, K.; Baldessarini, R.J. Long-term effects of newer antipsychotic drugs on neuronal nitric oxide synthase in rat brain. Nitric Oxide, 2002, 7, 297-300.
196. Suzuki, E.; Nakaki, T.; Shintai, F.; Kanba, S.; Miyaoka, H. Antopsychotic, antidepressant, anxiolytic, and anticonvulsant drugs induce type II nitric oxide synthase mRNA in rat brain. Neurosci. Lett., 2002, 333, 217-219.
197. Lipska, B.K.; Jaskiw, G.E.; Chrastusta, S.; Karoum, F.; Weinberger, D.R. Ibotenic lesion of the ventral hippocampus differentially affetcs dopmaine and its metabolites in the nucleus accumbens and prefrontal cortex in the rat. Brain Res., 1992, 585, 1-6.
198. Bernstein, H.-G.; Grecksch, G.; Becker, A.; Höllt, V.; Bogerts, B. Cellular changes in rat brain areas associated with neonatal hippocampal damage. Neuroreport, 1999, 10, 2307-2311
199. Negrete-Díaz, J.V.; Baltazar-Gaytán, E.; Bringas, M.E.; Vazquez-Roque, R.A.; Newton, S.; Aguilar-Alonso, P.; León-Chávez, B.A.; Flores, G. Neonatal ventral hippocampus lesion induces increase in NO levels which is attenuated by subchronic haloperidol treatment. Synapse, 2010, 64, 941-947.
200. Bernstein, H-G.; Becker, A.; Keilhoff, G.; Grecksch, G.; Bogerts B. Schizophrenia and the nitric oxide controversy: Do all things fall into place now? Synapse, 2011, 65, 545-546.
201. Tanda, K.; Nishi, A.; Matsuo, N.; Nakanish, K.; Yamasaki, N.; Toyama, K.; Takao, K.; Miyakawa, T. Abnormal social behavior, hyperactivity, impaired remote spatial memory, and increased D1mediated dopaminergic signaling in neuronal nitric oxide synthase knockout mice. Mol. Brain, 2009, 2, 19.
202. Freedman, R.; Adams, C.E.; Leonard, S. The alpha7-nicotinic acetylcholine receptor and the pathology of interneurons in schizophrenia. J. Chem. Neuroanat., 2000, 20, 299-306.
203. Gibbs, S.M. Regulation of neuronal proliferation and differentiation by nitric oxide. Mol. Neurosci., 2003, 27, 107-120
204. Mantelas, A.; Stamatakis, A.; Kazanis, I.; Philippidis, H.; Stylianopoulous, F. Control of neuronal nitric oxide synthase and brain-derived neurotrophic factor levels by GABA-A receptors in developing rat cortex. Brain Res. Dev. Brain Res., 2003, 145, 185-195.
205. McQuillen, P.S.; Ferriero, D.M. Selective vulnerability in the developing central nervous system. Pediatr. Neurol., 2004, 30, 227-235.
206. Fatemi, S.H.; Quadra, A.E.; El-Fakahany, E.E.; Sidwell, R.W.; Thuras, P. Prenatal viral infection causes alterations in NOS expression in developing mouse brains. Neuroreport, 2000, 11, 1493-1496.
207. Smith, K.J.; Lassmann, H. The role of nitric oxide in multiple sclerosis. Lancet Neurol., 2002, 1, 232-241.
208. Yao, S.Y.; Ljunggren-Rose, A.; Chandramohan, N.; Whetsell, W.O., Jr.; Sriram, S. In vitro and in vivo induction and activation of nNOS by LPS in oligodendrocytes. J. Neuroimmunol., 2010, 229, 146-156.
209. Uranova, N.A.; Vostrikov, V.M.; Orlovskaya, D.D.; Rachmanova, V.I. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr. Res., 2004, 67, 269-275.
210. Northoff, G.; Richter, A.; Bermpohl, F.; Grimm, S.; Martin, E.; Marcar, V.L.; Wahl, C.; Hell, D.; Boecker, H. NMDA hypofunction in the posterior cingulate as a model for schizophrenia: an exploratory ketamine administration study in fMRI. Schizophr. Res., 2005, 72, 235-248.
211. Dracheva, S.; McCurjk, S.R.; Haroutunian, V. mRNA expression of AMPA receptor binding proteins in the cerebral cortex of eldery schizophrenics. J. Neurosci. Res., 2005, 79, 868-878.
212. Reif, A.; Schmitt, A.; Fritzen, S.; Lesch, K.P. Neurogenesis and schizophrenia: dividing neurons in a divided mind? Eur. Arch. Psychiatry Clin. Neurosci., 2007, 257, 290-299.
213. Clinton, S.M.; Haroutunian, V.; Davis, K.L.; Meador-Woodruff, J.H. Altered transcript expression of NMDA receptor-associated postsynaptic proteins in the thalamus of subjects with schizophrenia. Am. J. Psychiatry, 2003, 160, 1100-1109.
214. Roberts, R.C.; Roche, J.K.; Conley, R.R. Synaptic differences in the postmortem striatum of subjects with schizophrenia: A stereological and ultrastructural analysis. Synapse, 2005, 56, 185-197.
215. Costa, E.; Davis, J.M.; Dong, E.; Grayson, D.R.; Guidotti, A.; Tremolizzo, L.; Veldic, M. A. GABAergic cortical deficit dominates schizophrenia pathophysiology. Crit. Rev. Neurobiol., 2004, 16, 1-23.
216. Das, I.; Ramchand, C.N.; Gliddon, A.; Hirsch, S.R. Nitric oxide, free radicals and polyamines may have a role in membrane pathology of schizophrenia. Neuropsychobiology, 1998, 37, 65-67
217. Das, U.N. Can memory be improved? A discussion on the role of ras, GABA, acetylcholine, NO, insulin, TNF-alpha, and long-chain polyunsaturated fatty acids in memory formation and consolidation. Brain Dev., 2003, 25, 251-261.
218. Prabakaran, S.; Swatton, J.E.; Ryan, M.M.; Huffaker, S.J.; Huang, J.T.; Griffin, J.L.; Wayland, M.; Freeman, T.; Dubbridge, F.; Lilley, K.S.; Karp, N.A.; Hester, S.; Tkachev, D.; Mimmack, M.L.; Yolken, R.H.; Webster, M.J.; Torrey, E.F.; Bahn, S. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry, 2004, 9, 684-697.
219. Dietrich-Muszalska, A.; Kontek, B. Lipid peroxidation in patients with schizophrenia. Psychiatry Clin. Neurosci., 2010, 64, 469-475
220. Narayan, S.; Thomas, E.A. Sphingolipid abnormalities in psychiatric disorders: a missing link in pathology? Front. Biosci., 2011, 16, 1797-1810.
221. Mahadik, S.P.; Mukherjee, S. Free radical pathology and and antioxidant defense in schizophrenia: a review. Schizophr. Res., 1996,19, 1-17.
222. Ranjekar, P.K.; Himnge, A.; Hedge, M.V.; Ghate, M.; Kale, A.; Sitasawad, S.; Wagh, U.V.; Debsikdar, V.B.; Mahadik, S.P. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res., 2003, 121, 109-122.
223. Ben-Shachar, D.; Laifenfeld, D. Mitochondria, synaptic plasticity, and schizophrenia. Int. Rev. Neurobiol., 2004, 59, 273-296
224. Mawrin, C.; Kirches, E.; Krause, G.; Schneider-Stock, R.; Bogerts, B.; Vorwerk, C.K.; Dietzmann, K. Region-specific analysis of mitochondrial DNA deletions in neurodegenerative disorders in humans. Neurosci. Lett., 2004, 357, 111-114.
225. Elibol, B.; Söylemezoglu, F.; Ünal, I.; Fujii, M.; Hirt, L.; Huang, P.L.; Moskwitz, M.A.; Dalkara, T. Nitric oxide is involved in ischemia-induced apoptosis in brain: a study in neuronal nitric oxide synthase deficient null mice. Neuroscience, 2001, 105, 79-86.
226. Keilhoff, G.; Seidel, B.; Reiser, M.; Stanarius, A.; Huang, P.L.; Bogerts, B.; Wolf, G.; Bernstein, H.-G. Lack of neuronal NOS has consequences for the expression of POMC and POMC-derived peptides in the mouse pituitary. Acta Histochem., 2001a, 103, 397-412.
227. Keilhoff, G.; Wolf, G.; Bernstein, H.-G. Altered laminar distribution of hippocampal zinc in mutant mice lacking neuronal nitric oxide synthase. A histochemical study. Neurosci. Lett., 2001b, 305, 173-176.
228. Mai, J.K.; Berger, K.; Sofroniew, M.V. Morphometric evaluation of neurophysin-immunoreactivity in the human brain: pronounced inter-individual variability and evidence for altered staining patterns in schizophrenia. J. Hirnforsch., 1993, 34, 133-154.
229. Iwahashi, K.; Yoneyama, H.; Ohnishi, T.; Nakamura, K.; Miyatake, R.; Suwaki, H.; Hosokawa, K.; Ichkawa, Y. Haloperidol inhibits neuronal nitric oxide synthase activity by preventing electron transfer. Neuropsychobiology, 1996, 33, 76-79.
230. Hu, J.; Lee, J.H.; El-Fakanhany, E.E. Inhibition of neuronal nitric oxide synthase by antipsychotic drugs. Psychopharmacology, 1996, 114, 161-166.
231. Nel, A.; Harvey, B.H. Haloperidol-induced dyskinesia associated with striatal NO synthase inhibition: reversal with olanzapine. Behav. Pharmacol., 2003, 14, 251-255.
232. Lau, Y.S.; Petroske, E.; Meredith, G.E.; Wang, J.Q. Elevated neuronal nitric oxide synthase expression in chronic haloperidoltreated rats. Neuropharmacology, 2003, 45, 986-994.
233. Palacios, M.; Padron, J.; Glaria, L.; Rojas, A.; Delgado, R.; Knowles, R.; Moncada, S. Chlorpromazine inhibits both the constitutive nitric oxide synthase and the induction of nitric oxide synthase after LPS challenge. Biochem. Biophys. Res. Commun., 1993, 196, 280-286.
234. []. Cook, C. Neurologic and psychiatric treatment with inhibitors of brain nitric oxide synthase. US Patent, 1996, 5527825. http.//pharmalicensing.com/licensing/displicopp/150
235. Salerno, I.; Sorrenti, V.; Di Giacomo, C.; Romeo, G.; Siracusa, M.A. Progress in the development of selective nitric oxide synthase (NOS) inhibitors. Curr. Pharm. Res., 2002, 8, 177-200.
236. Levkovitz, Y.; Mendlovich, S.; Riwkes, S.; Braw, Y.; Levkovitch-Verbin, H.; Gal, G.; Fennig, S.; Treves, I.; Kron, S. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J. Clin. Psychiatry, 2010, 71, 138-149.
237. Levkovitz, Y.; Levi, U.; Braw, Y.; Cohen, H. Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Res., 2007, 1154, 154-162.
238. Pålsson, E.; Fejgin, K.; Wass, C.; Engel, J.A.; Svensson, L; Klamer, D. The amino acid L-lysine blocks the disruptive effect of phencyclidine. on. prepulse. inhibition. in. mice. Psychopharmacology, 2007, 192, 9-15.
239. MacKay, M.; Cetin, M.; Baker, G.; Dursun, S. Modulation of central nitric oxide as a therapeutic strategy for schizophrenia. Klinik Psikofarmakoloji Bülteni, 2010, 20, 115-119.
240. Del Bel, E.A.; da Silva, C.A.; Guimarães, F.S.; Bermuda-Echeverry, M. Catalepsy induced by intra-striatal administration of nitric oxide synthase inhibitors in rats. Eur. J. Pharmacol., 2004, 485, 175-181.
241. Del-Bel, E.A.; Guimarães, F.S.; Joca, S.R.; Echeverry, M.B.; Ferreira, F.R. Tolerance to the cataleptic effect that follows repeated nitric oxide synthase inhibition may be related to functional enzymatic recovery. J. Psychopharmacol., 2010, 24, 397-405.
242. Deutsch S.I.; Rosse, R.B.; Paul, S.M.; Tomasino, V.; Koetzner, L.; Morn, C.B.; Mastropaolo, J. 7-nitroindazole and methylene blue, inhibitors of neuronal nitric oxide synthase and NO-stimulated guanylate cyclase, block MK-801-elicited behaviours in mice. Neuropsychopharmacology, 1996, 15, 37-43.
243. Surendran S, Rajasankar S. Parkinson's disease: oxidative stress and therapeutic approaches. Neurol. Sci., 2010, 31, 531-540
244. Candido, C.L.; Rommey, D.M. Depression in paranoid and nonparanoid schizophrenic patients compared with major depressive disorder. J. Affect. Diord., 2002, 70, 261-271.
245. Yu, Y.W.; Chen, T.J.; Wang, Y.C.; Liou, Y.L.; Hong, C.J.; Tsai, S.J. Association analysis for neuronal nitric oxide synthase gene polymorphism with major depression and fluorexetine response. Neuropsychobiology, 2003, 47, 137-140.
246. Buttenschön, H.N.; Mors, O.; Ewald, H.; McQuillin, A.; Kalsi, G.; Lawrence, J.; Gurling, H.; Kruse, T.A. No association between a neuronal nitric oxide synthase (NOS1) gene polymorphism on chromosome 12q24 and bipolar disorder. Am. J. Med. Genet. B, 2004, 124, 73-75.
247. Gałecki, P; Maes, M.; Florkowski, A.; Lewi ski, A.; Gałecka, E.; Bie kiewicz, M.; Szemraj, J. Association between inducible and neuronal nitric oxide synthase polymorphisms and recurrent depressive disorder. J. Affect. Disord., 2011, 129, 175-182.
248. Bernstein, H.-G.; Heinemann, A.; Krell, D.; Mawrin, C.; Bielau, H.; Danos, P.; Diekmann, S.; Keilhoff, G.; Bogerts, B.; Baumann, B. Further immunohistochemical evidence for impaired NO signaling in the hypothalamus of depressed patients. Ann. NY Acad. Sci., 2002, 973, 91-93.
249. Karolewicz, B.; Szebeni, K.; Stockmeier, C.A.; Konick, L.; Overholser, J.C.; Jurjus, G.; Roth, B.L.; Ordway, G.A. Low nNOS protein in the locus coeruleus in major depression. J. Neurochem.; 2004, 91, 1057-1066.
250. Chrapko, W.E.; Jurasz, P.; Radomski, M.W.; Lara, N.; Archer, S.L.; Le Melledo, J.M. Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder. Biol. Psychiatry, 2004, 56, 129-134.
251. Selley, M.L. Increased (E)-4-hydroxy-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression. J. Affect. Disord., 2004, 80, 249-254.
252. Wegener, G.; Volke, V.; Harvey, B.H.; Rosenberg, R. Local, but not systemic, administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity. Brain Res., 2003, 959, 128-134.
253. Wegener, G.; Volke, V. Nitric oxide inhibitors as antidepressants. Pharmaceuticals, 2010, 273-299.
254. Wegener, G.; Harvey, B.H.; Bonefeld, B.; Müller, H.K; Volke, V.; Overstreet, D.H.; Elfving, B. Increased stress-evoked nitric oxide signalling in the Flinders sensitive line (FSL) rat: a genetic animal model of depression. Neuropsychopharmacol., 2010, 13, 461-73
255. Sava, H.A.; Herken, H.; Yurekli, M.; Uz, E.; Tutkun, H.; Zoroǧlu, S.S.; Ozen, M.E.; Cengiz, B.; Akyol, O. Possible role of nitric oxide and adrenomedullin in bipolar affective disorder. Neuropsychobiology, 2002, 45, 57-61.